A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs - A north central cancer treatment group trial

Edatrexate is an antifolate agent with improved in vitro antineoplastic activity as compared with methotrexate. A Mayo phase I trial of edatrexate (E), vinblastine (V), doxorubicin (Adriamycin) (A), cisplatin (C), and filgrastim (GCSF), (EVAC-GCSF) showed promising antineoplastic activity in non-small-cell lung cancer (NSCLC) (Colon-Otero G, et al. Cancer J Sci Am 1997;3:297-302) leading to a phase 11 trial of this regimen, the results of which are reported here. A total of 34 patients with stage 11113 or IV measurable or evaluable NSCLC were entered in this North Central Cancer Treatment Group phase 11 study. Treatment consisted of edatrexate 100 mg/m(2) intravenously on day I and cisplatin 30 mg/m(2)/d on day I and day 2 followed by vinblastine 3 mg/m(2) intravenously and doxorubicin 30 mg/m(2) intravenously on day 2. Filgrastim was given at 300 mug subcutaneously daily from day 4 to day 18 or until an absolute neutrophil count of 2, 000/mm(3) Or More was obtained. Cycles were repeated every 21 days until either progression or the development of intolerable toxicity. Sixteen of 34 evaluable patients responded to therapy, for a response rate of 47.1% with a 95% CI of 30.3% to 63.8%. Median time to disease progression was 132 days, median survival time was 219 days, and the estimated 1-year survival was 41.2% (95% CI of 27.6-61.5%). The EVAC/G-CSF regimen has significant antineoplastic activity as seen by the response rates for patients with NSCLC. However, this study had significant myelosuppressive toxicity 56% patients had grade M or higher leukopenia with three treatment-related deaths observed. In addition, Quality of Life assessments indicate that patients experienced an overall decline in quality of life during the course of treatment. These mitigating factors need to be considered regarding further evaluation of this regimen in this patient population.